Ting Wang

Prof. Ting Wang

Anhui Medical University
orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Journal of Controlled Release
Verified
Journal Article
Closed access
NWNing Wang
Ning Wang
MCMinnan Chen
Minnan Chen
Ting WangTing Wang
Ting Wang

1 February 2006 in Biochimica et Biophysica Acta (BBA) - Biomembranes
Verified
Journal Article
Closed access
Ting WangTing Wang
Ting Wang
YDYingjie Deng
Yingjie Deng
YGYehui Geng
Yehui Geng
ZGZibin Gao
Zibin Gao
JZJianping Zou
Jianping Zou
ZWZhixuan Wang
Zhixuan Wang

1 September 2014 in European Journal of Pharmaceutics and Biopharmaceutics
Verified
Journal Article
Closed access
NWNing Wang
Ning Wang
Ting WangTing Wang
Ting Wang
MZMeiling Zhang
Meiling Zhang
RCRuonan Chen
Ruonan Chen
RNRuowen Niu
Ruowen Niu
YDYihui Deng
Yihui Deng

1 September 2011 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Ting WangTing Wang
Ting Wang
NWNing Wang
Ning Wang
HSHui Song
Hui Song
XXXiaonan Xi
Xiaonan Xi
JWJianAn Wang
JianAn Wang
TLTiefu Li
Tiefu Li

1 February 2015 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
Ting WangTing Wang
Ting Wang
YZYuanyuan Zhen
Yuanyuan Zhen
XMXiaoyu Ma
Xiaoyu Ma
BWBiao Wei
Biao Wei
SLShuqin Li
Shuqin Li
NWNing Wang
Ning Wang

17 September 2018 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
NLNing Li
Ning Li
NWNing Wang
Ning Wang
TWTingni Wu
Tingni Wu
CQChanglu Qiu
Changlu Qiu
XWXueting Wang
Xueting Wang
Ting WangTing Wang
Ting Wang
The curcumin (CUR)-hydroxypropyl-β-cyclodextrin (HP-β-CD) inclusion complex (CUR-HP-β-CD) was prepared to erase its therapeutic restrictions of poor aqueous solubility and low oral bioavailability. CUR-HP-β-CD was prepared by a simple procedure of water-ethanol cosolvent incubation-lyophilization which may be suitable for scale up production, and characterized by Fourier transform-infrared spectroscopy (FT-IR), powder X-ray diffractometry (PXRD), differential scanning calorimetry (DSC), phase solubility method and dissolution study; the in vitro cytotoxicity was assayed by MTT, whereas the in vivo pharmacokinetics was tested by HPLC in rats receiving formulations via intravenous and oral administration, respectively. CUR was successfully encapsulated in HP-β-CD with a loading capacity of about 1:7 of CUR to HP-β-CD mole ratio, which remarkably enhanced drug water solubility and maintained well the antitumour activity of CUR. The CUR-HP-β-CD and free CUR have a similar pharmacokinetic behaviour in rats after intravenous administration; however, the oral bioavailability of CUR was enhanced to 2.77-fold by the HP-β-CD. The CUR-HP-β-CD can be successfully prepared by a simple method, which may be feasible for industrial scaling up, to remarkably increase drug water solubility and oral bioavailability while maintaining its bioactivity and may be a promising therapeutic preparation.